Bispecific Antibodies Stocks
Next-generation immunotherapy platforms develop engineered proteins designed to bind simultaneously to two distinct epitopes or antigens, overcoming the limitations of traditional monoclonal antibodies.
As of Oct 23, 2026, Bispecific Antibodies has 23 US-listed companies worth $61.8B combined. The median member moved +8.3% over the past week; BCAB led at +25.7% and MGNX trailed at -30.8%.
Companies in Bispecific Antibodies
- GMAB – Genmab AS, $26.9B
- SMMT – Summit Therapeutics PLC, $12.3B
- TGTX – TG Therapeutics Inc, $8.1B
- CLDX – Celldex Therapeutics Inc, $2.3B
- ZYME – Zymeworks Inc. Common Stock, $1.9B
- XNCR – Xencor Inc, $1.9B
- COAG – Hemab Therapeutics Holdings, Inc. Common Stock, $1.7B
- IMCR – Immunocore Holdings Ltd, $1.5B
- IMTX – Immatics NV, $1B
- CGEM – Cullinan Oncology LLC, $961M
- STTK – Shattuck Labs Inc, $548M
- CBIO – Crescent Biopharma, Inc., $532M
- ACRS – Aclaris Therapeutics Inc, $483M
- ZURA – Zura Bio Limited Class A Ordinary Shares, $396M
- SRZN – Surrozen Inc, $276M
- MGNX – MacroGenics Inc, $218M
- ADAG – Adagene Inc, $165M
- NBP – NovaBridge Biosciences, $158M
- VRXA – Veraxa Biotech AG Ordinary Shares, $156M
- CMPX – Compass Therapeutics Inc., $150M
- CNTX – Context Therapeutics Inc, $28.9M
- APVO – Aptevo Therapeutics Inc, $3.1M
- BCAB – Bioatla Inc, $2.5M